Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment

BACKGROUND: Hepatitis B surface antigen (HBsAg) loss/seroconversion is considered to be an ideal endpoint for antiviral therapy and a final therapeutic target for chronic hepatitis (CHB). This study aimed to evaluate the HBsAg kinetics in CHB patients during peginterferon-a (Peg-IFN-a) treatment. MA...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kaifa, Huang, Guangyu, Chen, Yagang, Wang, Yuming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339975/
https://www.ncbi.nlm.nih.gov/pubmed/32587233
http://dx.doi.org/10.12659/MSM.921487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339975/
https://www.ncbi.nlm.nih.gov/pubmed/32587233
http://dx.doi.org/10.12659/MSM.921487

Ejemplares similares